Факти та гіпотези антибактеріальної терапії в кардіології
DOI:
https://doi.org/10.37987/1997-9894.2017.7(213).222350Анотація
Метою статті було вивчення та надання даних аналізу актуальних рекомендацій щодо застосування антибактеріальної терапії в кардіологічній практиці. Крім того, в цьому огляді приділено увагу результатам деяких опублікованих на даний час досліджень, даним літератури щодо впливу антибіотиків на ризик розвитку та профілактику ішемічної хвороби серця та інфаркту міокарда.
Посилання
ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) / G. Habib, P. Lancellotti, M.J. Antunes [et al.] // Eur. Heart J. – 2015. Aug 29. [Epub ahead of print].
Cosgrove S.E. Initial low-dose gentamicin for staphylococcus aureus bacteremia and endocarditis is nephrotoxic / S.E. Cosgrove, G.A. Vigliani, V.G. Fowler et al. // Clin. Infect. Dis. – 2009. – Vol. 48. – P. 713–721.
Miro J.M. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus / J.M. Miro, C. Garcia-de-la-Maria, Y. Armero et al. // Antimicrob. Agents Chemother. – 2009. – Vol. 53. – P. 4172–4177.
Kullar R. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis / R. Kullar, A.M. Casapao, S.L. Davis et al. // J. Antimicrob. Chemother. – 2013. – Vol. 68. – P. 2921–2926.
Francioli P. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study / P. Francioli, W. Ruch, D. Stamboulian // Clin. Infect. Dis. – 1995. – Vol. 21. – P. 1406–1410.
Casalta J.P. Treatment of staphylococcus aureus endocarditis with high doses of trimethoprim/sulfamethoxazole and clindamycin—preliminary report / J.P. Casalta, C. Zaratzian, S. Hubert et al. // Int. J. Antimicrob. Agents. – 2013. – Vol. 42. – P. 190–191.
Riedel D.J. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus / D.J. Riedel, E. Weekes, G.N. Forrest // Antimicrob. Agents Chemother. – 2008. – Vol. 52. – P. 2463–2467.
Miro J.M. High-dose daptomycin plus fosfomycin is safe and effective in aureus endocarditis / J.M. Miro, J.M. Entenza, M. Velasco, X. Castaneda et al. // Antimicrob. Agents Chemother. – 2012. – Vol. 56. – P. 4511–4515.
Rose W.E. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations / W.E. Rose, S.N. Leonard, G. Sakoulas et al. // Antimicrob. Agents Chemother. – 2008. – Vol. 52. – P. 831–836.
del Rio Gasch O. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial / O. del Rio Gasch, A. Moreno, C. Pena, J. Cuquet et al. // Clin. Infect. Dis. – 2014. – Vol. 59. – P. 1105–1112.
Tattevin P. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study / P. Tattevin, D. Boutoille, V. Vitrat et al. // J. Antimicrob. Chemother. – 2014. – Vol. 69. – P. 2010–2013.
Пайл К. Диагностика и лечение в ревматологии. Проблемный подход. Перевод с англ. / К. Пайл, Л. Кеннеди / Под ред. Н.А. Шостак. – М.: Гэотар-Медиа, 2011.
Насонова С.Л. Клинические рекомендации. Ревматология. 2-е изд. / С.Л. Насонова // Ревматология: национальное руководство. – М.: Гэотар-Медиа, 2010. – 711 с.
Рекомендации РНМОТ и ОССН по диагностике и лечению миокардитов / Под ред. Е.В. Шляхто. – Москва, 2012.
Meier C.R. Antibiotics in the prevention and treatment of coronary heart disease / C.R. Meier // The Journal of Infectious Diseases. – 2000. – №181(Suppl. 3). – Р. 558–562.
American Heart Association 2000 heart and stroke statistical update. – Dallas: AHA, 1999.
Sans S. The burden of cardiovascular disease mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe / S. Sans, H. Kesteloot, D. Kromhout // Eur. Heart J. – 1997. – Vol. 18. – P. 1231–1248.
Grayston J.T. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections / J.T. Grayston, C. Kuo, S. Wang, J. Altman // Engl. J. Med. – 1986. Vol. 315. – P. 161–168.
Fagerberg B. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease / B. Fagerberg, J. Gnarpe, Н. Gnarpe, S. Agewall, J. Wikstrand // Stroke. – 1999. – Vol. 30. – P. 299–305.
Strachan D.P. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischemic heart disease over 13 years in the Caerphilly prospective heart disease study / D.P. Strachan, D. Carrington, M.A. Mendall, et al. // BMJ. – 1999. – Vol. 318. – P. 1035–1040.
Ridker P.M. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction / P.M. Ridker, R.B. Kundsin, M.J. Stampfer, S. Poulin, C.H. Hennekens // Circulation. – 1999. – Vol. 99. – P. 1161–1164.
Nieto F.J. Chlamydia pneumoniae infection and incident coronary heart disease: the atherosclerosis risk in communities study / F.J. Nieto, A.R. Folsom, P.D. Sorlie, J.T. Grayston, S.P. Wang, L.E. Chambless // Am. J. Epidemiol. – 1999. – Vol. 150. – P. 149–156.
Jackson L.A. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma / L.A. Jackson, L.A. Campbell, R.A. Schmidt et al. // Am. J. Pathol. – 1997. – Vol. 150. – P. 1785–1790.
Kuo C. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15–34 years old) / C. Kuo, J.T. Grayston, L.A. Campbell, Y.A. Goo et. al. // Proc. Natl. Acad. Sci USA. – 1995. – Vol. 92. – P. 6911–6914.
Ramirez J.A. Chlamydia pneumoniae/Atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis / J.A. Ramirez // Ann. Intern. Med. – 1996. – Vol. 125. – P. 979–982.
Laitinen K. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits / K. Laitinen, A. Laurila, L. Pyhala, M. Leinonen, P. Saikku // Infect. Immun. – 1997. – Vol. 65. – P. 4832–4835.
Muhlestein J.B. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model / J.B. Muhlestein, J.L. Anderson, E.H. Hammond et al. // Circulation. – 1998. – Vol. 97. – P. 633–636.
Hu H. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae / H. Hu, G.N. Pierce, G. Zhong // J. Clin. Invest. – 1999. – Vol. 103. – P. 747–753.
Kauppinen M. Pneumonia due to Chlamydia pneumoniae; prevalence, clinical features, diagnosis, and treatment / M. Kauppinen, P. Saikku // Clin. Infect. Dis. – 1995. – Vol. 21 (suppl. 3). – P. 244–252.
Cook P.J. Clinical aspects of Chlamydia pneumoniae infection / P.J. Cook, D. Honeybourne // Presse Med. – 1995. – Vol. 24. – P. 278–282.
Hyman C.L. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment of polymerase chain reactionenzyme immunoassay and culture / C.L. Hyman, P.M. Roblin, C.A. Gaydos, T.C. Quinn, J. Schachter, M.R. Hammerschlag // Clin. Infect. Dis. – 1995. – Vol. 20. – P. 1174–1178.
Kuo C. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae / C. Kuo, L.A. Jackson LA, A. Lee, J.T. Grayston // Antimicrob. Agents Chemother. – 1996. – Vol. 40 – P. 2669–2670.
Gurfinkel E. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study / E. Gurfinkel, G. Bozovich, A. Daroca, E. Beck, B. Mautner // Lancet. – 1997. – Vol. 350. – P. 404–407.
Gupta S. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction / S. Gupta, E.W. Leatham, D. Carrington, M.A. Mendall, J.C. Kaski, J. Camm // Circulation. – 1997. – Vol. 96. – P. 404–407.
Gurfinkel E. Treatment with the antibiotic roxithromycin in patients with acute non–Q-wave coronary syndromes / E. Gurfinkel, G. Bozovich, E. Beck, E. Testa, B. Livellara, B. Mautner for the ROXIS Study Group // Eur. Heart. J. – 1999. – Vol. 20 – P. 121–127.
Anderson J.L. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection / J.L. Anderson, J.B. Muhlestein, J. Carlquist, A. Allen, S. Trehan, C. Nielson // Circulation. – 1999. – Vol. 99. – P. 1540–1547.
Martin D. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes / D. Martin, J. Bursill, M.R. Qui, S.N. Breit, T. Campbell // Lancet. – 1998. – Vol. 351. – P.1858–1859.
Rajagopalan S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability / S. Rajagopalan, X.P. Meng, S. Ramasamy, D.G. Harrison, Z.S. Galis // J. Clin. Invest. – 1996. – Vol.98. – P. 2572–2579.
Meier CR. Antibiotics and risk of subsequent first-time myocardial infarction / C.R. Meier, L.E. Derby, S.S. Jick, C. Vasilakis, H. Jick // JAMA. – 1999. – Vol. 281. – P. 427–431.
